AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

A phase 3 study has shown that when compared with placebo, Tezspire provided a statistically significant and clinically ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Dr. med. Rainer Weber 1. Kato A, Schleimer RP, Bleier BS: Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol 2022; 149: 1491–503 CrossRef MEDLINE PubMed Central 2.

No writing assistance was utilized in the production of this manuscript. Chronic rhinosinusitis is one of the most common clinical syndromes in the USA. The etiology of chronic rhinosinusitis is ...

Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps ...

A study published in Frontiers in Medicine reveals that chronic rhinosinusitis with and without nasal polyps is closely correlated with asthma.A study was done to investigate the ...

CRSwNP is a chronic condition that affects up to 4% of the general population, of whom 40% have uncontrolled disease. It is caused by inflammation of the nasal lining that can lead to soft tissue ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...